Article

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapy

2021-06-09

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold>Patients with stage II to III breast cancer have a high recurrence rate. The early detection of recurrent breast cancer remains a major unmet need. Circulating tumor DNA (ctDNA) has been shown to be a marker to detect disease progression in metastatic breast cancer. We aimed to evaluate the prognostic value of ctDNA in the setting of neoadjuvant therapy (NAT).<bo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 32d924c3-16ec-505c-9f4c-e2c8d1c33556
DOI: 10.21203/rs.3.rs-598665/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapyDOI 10.21203/rs.3.rs-598665/v1Read

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialSemantic proximity Read

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read

Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stages I-III colorectal cancerSemantic proximity Read

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assaySemantic proximity Read

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid TumorsSemantic proximity Read